Novo Holdings A/S — 13F Holdings & Portfolio
CIK 1388325 · latest 13F-HR filed 2026-05-15
Novo Holdings A/S manages $1.23B in 13F-reported U.S. long-equity assets across 22 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are EWTX (13.65%), BN (11.46%), ASML (10.16%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 3, added to 9, and trimmed 9.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.23B
Long-equity book
22
Distinct positions
2026-03-31
Filed 2026-05-15
+1 / −3 / ↑9 / ↓9
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- EDGEWISE THERAPEUTICS INC$35.8M +26.9%
- ENLIVEN THERAPEUTICS INC$27.4M +120.1%
- MIRUM PHARMACEUTICALS INC$22.6M +22.6%
- MAPLIGHT THERAPEUTICS INC$10.2M +15.7%
- VAXCYTE INC$7.7M +18.2%
Top Trims
- VIRIDIAN THERAPEUTICS INC-$34.9M -47.2%
- CRINETICS PHARMACEUTICALS IN-$19.3M -25.6%
- BROOKFIELD CORP-$18.9M -11.8%
- SALESFORCE INC-$14.1M -16.1%
- VALNEVA SE-$13.7M -67.5%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $168.5M | 13.65% | 5,350,000 | SH |
| 2 | BROOKFIELD CORP | BN | 11271J107 | $141.5M | 11.46% | 3,496,245 | SH |
| 3 | ASML HOLDING N V | ASML | N07059210 | $125.4M | 10.16% | 94,946 | SH |
| 4 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $122.4M | 9.92% | 1,325,000 | SH |
| 5 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $74.9M | 6.07% | 3,686,622 | SH |
| 6 | SALESFORCE INC | CRM | 79466L302 | $73.4M | 5.95% | 393,187 | SH |
| 7 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $56.3M | 4.56% | 1,550,000 | SH |
| 8 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $50.2M | 4.07% | 1,280,000 | SH |
| 9 | VAXCYTE INC | PCVX | 92243G108 | $50.0M | 4.05% | 860,000 | SH |
| 10 | PHARVARIS N V | PHVS | N69605108 | $49.4M | 4.01% | 1,750,000 | SH |
| 11 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $44.8M | 3.63% | 1,942,142 | SH |
| 12 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $39.1M | 3.17% | 2,000,000 | SH |
| 13 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $38.1M | 3.08% | 1,200,000 | SH |
| 14 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $37.9M | 3.07% | 450,000 | SH |
| 15 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $37.3M | 3.02% | 660,000 | SH |
| 16 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $34.0M | 2.75% | 3,650,737 | SH |
| 17 | ALIBABA GROUP HLDG LTD | BABA | 01609W102 | $32.3M | 2.62% | 257,327 | SH |
| 18 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $28.2M | 2.29% | 485,438 | SH |
| 19 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $19.6M | 1.59% | 2,185,923 | SH |
| 20 | VALNEVA SE | VALN | 92025Y103 | $6.6M | 0.54% | 1,057,421 | SH |
| 21 | LANZATECH GLOBAL INC | LNZA | 51655R200 | $2.5M | 0.21% | 158,148 | SH |
| 22 | MARQETA INC | MQ | 57142B104 | $1.8M | 0.15% | 441,558 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $1.23B | 22 | 0001388325-26-000026 |
| 2025-12-31 | 2026-02-17 | $1.29B | 24 | 0001388325-26-000007 |
| 2025-09-30 | 2025-11-14 | $1.55B | 27 | 0001388325-25-000025 |